Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Daily News ESC 2023

Dietary Nitrate Dramatically Cuts Contrast-Induced Nephropathy: NITRATE-CIN

Michael O'Riordan

August 30, 2023

News Daily News

ACS Care in Older Patients Entails Unique Risks, Shifting Goals, Says AHA

Todd Neale

December 16, 2022

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Todd Neale

August 28, 2022

News Daily News

Acute MI Workup in Emergency Departments Varies by Sex and Race

Michael O'Riordan

May 11, 2022

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Daily News

Statins Positively Alter Coronary Plaque Composition

Michael O'Riordan

August 23, 2021

News Daily News

Traditional Cath Lab Practices Scrutinized, Some Debunked, in AHA Statement

Todd Neale

July 05, 2021

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

News Daily News

PCI Volumes Rise in US and Japan, but for Different Reasons

Michael O'Riordan

September 14, 2020

News Conference News ESC 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

Yael L. Maxwell

September 08, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Shelley Wood

January 20, 2020

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Advertisement

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Dietary Nitrate Dramatically Cuts Contrast-Induced Nephropathy: NITRATE-CIN

ACS Care in Older Patients Entails Unique Risks, Shifting Goals, Says AHA

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Acute MI Workup in Emergency Departments Varies by Sex and Race

Managing AF Patients Undergoing PCI—Some Lingering Questions

Heterozygous FH Diagnosed Late, Remains Undertreated

Statins Positively Alter Coronary Plaque Composition

Traditional Cath Lab Practices Scrutinized, Some Debunked, in AHA Statement

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

PCI Volumes Rise in US and Japan, but for Different Reasons

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content